Frozen section analysis (FS) of the distal urethral margin is used to determine the feasibility of orthotopic reconstruction or the need for simultaneous urethrectomy in patients undergoing radical cystectomy for the treatment of bladder cancer. Despite the fact that this practice represents the contemporary standard of care, scant data exist upon which to base an evaluation of the accuracy and reliability of urethral FS at the time of surgery. We sought to determine the positive and negative predictive values of urethral FS by analyzing our clinical experience.
INTRODUCTION AND OBJECTIVES:
Frozen section analysis (FS) of the distal urethral margin is used to determine the feasibility of orthotopic reconstruction or the need for simultaneous urethrectomy in patients undergoing radical cystectomy for the treatment of bladder cancer. Despite the fact that this practice represents the contemporary standard of care, scant data exist upon which to base an evaluation of the accuracy and reliability of urethral FS at the time of surgery. We sought to determine the positive and negative predictive values of urethral FS by analyzing our clinical experience.
METHODS: The IRB-approved, institutional urothelial cancer database (2000) (2001) (2002) (2003) (2004) (2005) (2006) (2007) (2008) (2009) (2010) (2011) (2012) was reviewed for patients undergoing radical cystectomy in which FS had been performed to assess distal urethral margins. We compared urethral FS status with that of the final urethral margin section in order to calculate the positive and negative predictive values of the FS. The cases of positive urethral FS were then specifically analyzed to assess rates of urethral recurrence and survival.
RESULTS: 750 patients with complete pathologic information underwent cystectomy for bladder cancer at our institution during this period (median follow-up, 36.9 months). Urethral FS were sent in 322 cases (43%). All patients with a negative FS were confirmed to have a negative margin on final pathology, resulting in a negative predictive value of 100%. Urethral FS were positive in 28 patients (8.7%), of which 13 (46%) ultimately had negative margins on final pathology, yielding a positive predictive value of 54%. Of the patients with positive urethral FS, 3 underwent urethrectomy (1 concurrent, 2 delayed). Four patients with positive final urethral margins had urethral recurrences (median follow up 29.1 months). These individuals were subsequently treated with adjuvant chemotherapy (2 patients) and urethrectomy (2 patients). No differences in freedom from urethral recurrence or overall survival were seen between those in whom positive FS remained positive (true positive) and those in whom positive FS became negative on final pathology (false positive).
CONCLUSIONS: A negative urethral FS reliably identifies individuals for whom urethrectomy is unnecessary and provides robust information for decision-making regarding the safety of orthotopic reconstruction. Nearly half of the patients with a positive FS were ultimately determined to have a negative final margin. Accordingly, we recommend that surgeons and pathologists discuss positive FS findings at the time of surgery and consider whether additional tissue should be analyzed in real time if practical. The pattern of bladder cancer metastasis has been well described in the literature, with liver, lung, bone, and brain being the most common sites. We hypothesize that bladder sparing therapy with chemotherapy and external beam radiation therapy (XRT) alters the normal lymphatic drainage and leads to abnormal patterns of tumor metastasis. METHODS: From 1989 -2002 patients with biopsy proven bladder transitional cell carcinoma underwent bladder-sparing treatment with chemotherapy (cisplatin and 5-FU) and XRT. All patients had a CT urogram or retrograde pyelogram showing no evidence of nodal or metastatic disease at presentation. Location of the initial tumor burden was documented, and patients underwent frequent transuretheral resections with pathologic analysis to monitor for occurrence and location of recurrent tumors. Recurrence was treated either with resection and intravesical BCG or cystectomy. Risk factors for progression and mortality, as well as location of metastases, were assessed. Kaplan-Meier and Cox proportional hazards models were used for statistical analysis.
RESULTS: Of the 102 patients in this series, the mean age at cancer diagnosis was 64 years (36-85 years) with median follow up of 153 months (2-791 months). Sixty-two patients developed local recurrence (61%), with median time to recurrence of 8.7 months (1-476). Sixteen of these patients were treated with Intravesical BCG and 24 were treated with cystectomy (16/62, 26%; 24/62, 39%). Forty-three patients developed metastases (41%), with median time to identification of 60 months (4-483). Twenty-seven patients had nodal metastases (27/102, 26%); 10/27 were isolated to the lymph nodes (37%; 5/9 thoracic, 4/9 retroperitoneal, 1/9 both) and 17/27 had additional visceral metastases (63%; 6/27 thoracic, 7/27 retroperitoneal, 4/27 both). Thirtythree developed distant visceral metastases (33/102, 32%), 16/34 of which were without identified nodal involvement (47%). Twenty-four had one site of visceral metastasis and 9/33 had between 2-6 sites (24/33, 73%; 9/33, 27%). Sites of metastasis included lung (11), bone (9), liver (9), bowel (7), adrenals (3), brain (3), skin (2), diaphragm (2), chest wall (1), pancreas (1), pericardium (1), and urinary system (1). Sixty-four patients were deceased at follow-up (63%), with median time from diagnosis to death of 95 months (5-573).
CONCLUSIONS: Bladder sparing therapy with chemotherapy and XRT alters metastatic spread of the disease with a higher rate of metastases to the bowel, skin, and diaphragm than has been reported for bladder TCC. Local tumor invasion has been individuated as the most important prognostic factor in patients affected by bladder cancer (BCa). However, carcinoma in situ (CIS) is a recognized factor for recurrence and progression in BCa. In patients treated with radical cystectomy (RC), the absence of residual urothelial tumor (pT0) is associated to better survival as compared to other BCa stages. We sought to evaluate the impact of carcinoma in situ (pTis) as the only remaining BCa on recurrence, overall survival (OS) and cancer specific survival (CSS), as compared to patients who harbor pT0 at final pathology.
METHODS: The study focused on 1,280 consecutive non metastatic bladder cancer (BCa) patients treated with RC at a single tertiary care referral center between January 1994 and August 2013. No patients received neoadjuvant chemotherapy. Patients with pT0 or pTis at radical cystectomy specimen were included in the study. KaplanMeier analyses were used to assess long term recurrence, CSS and OS in pT0 vs. pTis patients. Cox regression analyses were used to test the role of pTis on the same outcomes, after adjusting for nodal status and age at surgery. RESULTS: Overall, 128 (10.0%) patients were included in the study. Of these, 57 (45.5%) and 71 (55.5%) patients harbored either pT0 or pTis, respectively. In 8 (6.2%) patients, node metastases were recorded. Median years of follow up was 6 years. gene expression have been found to be resistant to neoadjuvant chemotherapy (NAC) with methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC). We investigated the response of these subtypes to gemcitabine plus cisplatin (GC), the other major frontline NAC regimen in this disease setting. METHODS: Fifty-two MIBC patients received neoadjuvant GC followed by cystectomy. At cystectomy, 37 (71%) patients did not respond to NAC (ypT2 or any ypN1-3). With the RNeasy FFPE kit (Qiagen) RNA was isolated from pre-NAC transurethral resection (TUR) specimens and post-NAC cystectomy specimens. After cDNA ampliciation and labelling with the Ovation WTA FFPE system and Encore Biotin Module (NuGen) samples were hybridized to GeneChip Human Exon 1.0 ST oligonucleotide microarrays (Affymetrix). The tumors were assigned to the intrinsic subtypes using a one nearest neighbor prediction model. RESULTS: Unsupervised hierarchical clustering separated the tumors into clusters characterized by non-overlapping expression of basal or luminal biomarkers. Assignment of pretreatment TUR tumors to subtypes yielded the expected ratios of basal, p53-like, and luminal tumors of which 5/14 (36%), 2/15 (17%) and 8/23 (35%) showed pathological down staging (<ypT2 any ypN neg), respectively. p53-like tumors had significantly the shortest recurrence free (p¼0.006) and overall survival (p¼0.003) compared to the other subtypes. Basal tumors with an enrichment of an immune signature responded to NAC, although this did not reach statistical significance. Matched analysis of tumors before and after NAC revealed an enrichment for p53-like tumors at cystectomy.
CONCLUSIONS: In line with the MVAC data, p53-like tumors displayed resistance to neoadjuvant GC. Moreover, p53-ness is associated with unfavorable outcome in MIBC treated with NAC. If these results are confirmed prospectively, patients with p53-like tumors should not be treated with cisplatin-based chemotherapy and should instead be steered to immediate cystectomy or clinical trials of novel therapies. METHODS: We retrospectively reviewed our database for patients who underwent radical cystectomy and lymphadenectomy with curative intent for urothelial carcinoma of the bladder. Clinical and pathologic data were evaluated. Patients were analyzed in three groups according to node positivity: node negative, single positive lymph node, and more than one positive lymph node. Kaplan-Meier analysis with log rank test was performed to evaluate disease specific survival. Multivariable Cox regression modeling (including pathologic T stage, lymphovascular invasion, number of removed lymph nodes and adjuvant chemotherapy) was performed to evaluate associations between node positivity and survival.
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RESULTS: In total, 1202 patients met the inclusion criteria. Of them, 862 (71.7%) patients had node negative disease, 123 (10.2%) had single positive lymph node and 217 (18%) had more than one positive lymph node. Five-year recurrence-free survival rates were 74.5 % for node negative disease, 45.2% for those with single positive lymph node (p<0.001) and 35.6% for those with more than one positive lymph node (p¼0.031). Subgroup analysis according to organ confinement revealed that single positive lymph node with organconfined disease (pT2 or less) has the same survival as node negative disease with extravesical involvement (pT3 or more) 55.5% vs. 54.3% (p¼0.064). (Figure 1 ) Multivariable analysis identified the number of positive lymph nodes and the presence of extravesical disease as predictors of lower recurrence-free survival (HR 2.43, p ¼0.031 and HR 2.25, p¼0.015, respectively).
CONCLUSIONS: Single positive lymph node involvement reduces the survival by more than 20%. Single positive lymph node involvement with organ confined disease is associated with equivalent survival outcomes to node negative extravesical disease. Adjuvant therapy may be required in these patients.
